TPL2 (Therapeutic Targeting Tumor Progression Locus-2)/ATF4 (Activating Transcription Factor-4)/SDF1α (Chemokine Stromal Cell-Derived Factor-α) Axis Suppresses Diabetic Retinopathy
Authors:
- De-Wei LaiDLDe-Wei Lai
- Keng-Hung LinKLKeng-Hung Lin
- Wayne Huey-Herng SheuWSWayne Huey-Herng Sheu
- Maw-Rong LeeMLMaw-Rong Lee
- Chung-Yu ChenCCChung-Yu Chen
- Wen-Jane LeeWLWen-Jane Lee
- Yi-Wen HungYHYi-Wen Hung
- Chin-Chang ShenCSChin-Chang Shen
- Tsung-Ju ChungTCTsung-Ju Chung
- Shing-Hwa LiuSLShing-Hwa Liu
- Meei-Ling SheuMSMeei-Ling Sheu
- 1 September 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 121 (6) , e37-e52
Abstract
Rationale:: Diabetic retinopathy is characterized by vasopermeability, vascular leakage, inflammation, blood–retinal barrier breakdown, capillary degeneration, and neovascularization. However, the mechanisms underlying the association between diabetes mellitus and progression retinopathy remain unclear. Objective:: TPL2 (tumor progression locus 2), a serine-threonine protein kinase, exerts a pathological effect on vascular angiogenesis. This study investigated the role of N ε -(carboxymethyl)lysine, a major advanced glycation end products, and the involved TPL2-related molecular signals in diabetic retinopathy using models of in vitro and in vivo and human samples. Methods and Results:: Serum N ε -(carboxymethyl)lysine levels and TPL2 kinase activity were significantly increased in clinical patients and experimental animals with diabetic retinopathy. Intravitreal administration of pharmacological blocker or neutralizing antibody inhibited TPL2 and effectively suppressed the pathological characteristics of retinopathy in streptozotocin-induced diabetic animal models. Intravitreal VEGF (vascular endothelial growth factor) neutralization also suppressed the diabetic retinopathy in diabetic animal models. Mechanistic studies in primary human umbilical vein endothelial cells and primary retinal microvascular endothelial cells from streptozotocin-diabetic rats, db/db mice, and samples from patients with diabetic retinopathy revealed a positive parallel correlation between N ε -(carboxymethyl)lysine and the TPL2/chemokine SDF1α (stromal cell–derived factor-α) axis that is dependent on endoplasmic reticulum stress-related molecules, especially ATF4 (activating transcription factor-4). Conclusions:: This study demonstrates that inhibiting the N ε -(carboxymethyl)lysine-induced TPL2/ATF4/SDF1α axis can effectively prevent diabetes mellitus–mediated retinal microvascular dysfunction. This signaling axis may include the therapeutic potential for other diseases involving pathological neovascularization or macular edema.Keywords
This publication has 45 references indexed in Scilit:
- RANIBIZUMAB FOR DIABETIC MACULAR EDEMA REFRACTORY TO MULTIPLE PRIOR TREATMENTSRetina, 2016
- Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) as a therapeutic target to prevent retinal vasopermeability during diabetesProceedings of the National Academy of Sciences, 2016
- Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular oedema after multiple anti-VEGF injectionsEye, 2016
- INTRAVITREAL DEXAMETHASONE IMPLANT IN PATIENTS WITH RANIBIZUMAB PERSISTENT DIABETIC MACULAR EDEMARetina, 2015
- Evidence for Anti-VEGF Treatment of Diabetic Macular EdemaOphthalmic Research, 2012
- Activation of Endoplasmic Reticulum Stress by Hyperglycemia Is Essential for Müller Cell–Derived Inflammatory Cytokine Production in DiabetesDiabetes, 2012
- Effect of systemic medications on onset and progression of diabetic retinopathyNature Reviews Endocrinology, 2010
- Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetesExpert Opinion on Drug Delivery, 2010
- Intraocular expression of endostatin reduces VEGF‐induced retinal vascular permeability, neovascularization, and retinal detachmentThe FASEB Journal, 2003
- Vascular Endothelial Growth Factor–Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective β-Isoform–Selective InhibitorDiabetes, 1997